During this OBD guest speaker series, Dr Clifford Jack provides an invaluable reminder to us all on the history of how the NIA-AA framework came into existence, the evolution of the ATN framework and openly talks around the contraversial viewpoints for the disease condition. With the upcoming draft review of the NIA-AA Clinical Criteria for Alzheimer’s Disease (AD), it is timely for us all to reflect upon how complex Alzheimer's disease actually is. We look forward to seeing the final version of the updated NIA-AA guideline document soon.
The laboratory of Clifford R. Jack Jr., M.D., is engaged in brain imaging research in cognitive aging, Alzheimer's disease and related disorders. Dr. Jack's research team employs MRI and positron emission tomography (PET) to study the biology of brain aging and causes of cognitive impairment and develops image-processing algorithms for quantitatively measuring the information obtained from brain imaging. They employ a variety of MRI-based brain imaging modalities, including structural MRI, spectroscopy, functional connectivity and brain water diffusion. They also employ F-fluorodeoxyglucose positron emission tomography (FDG-PET) and amyloid PET.
The lab's clinical imaging research is tightly integrated into the Mayo Clinic Alzheimer's Disease Patient Registry (Mayo Clinic Study of Aging) and Mayo's Alzheimer's Disease Research Center, which conduct National Institutes of Health-funded longitudinal clinical and epidemiological research projects investigating normal aging, Alzheimer's disease and other dementias.
Dr. Jack also collaborates with a number of investigators outside Mayo, and his laboratory is the imaging center for several large national multisite studies.
5 сен 2024
